ART-100 / Arum Therap - LARVOL DELTA

Treatment of Mycoplasma genitalium and detection of macrolide resistance mutations (23S rRNA) in PHIV and HIV‐negative individuals (HIV-Glasgow 2024) - "Epidemiological characteristics Characteristics Details Gender Male 90.63% (58), female 9.38% (6) Age (median) 31.5 years (IQR 27-42.5) MSM (among males) 78.13% (50), 82.8% (48/58) Country of origin Spain 72%, Latin America 23.5%, others 4.5% PrEP-HIV users Daily PrEP 54.7%, on-demand PrEP 79.5%, duration on PrEP (months): 9 (IQR 4–21) PHIV (previously known) Duration of HIV infection (years): 8 (IQR 1–12), AIDS 20%, on ART 100%, virally suppressed (HIV VL <50 copies/ml) 71.4% Chemsex 14.75% Slamsex 1.67% Observed MG prevalence is higher (14%) than expected. Observed MG prevalence is higher (14%) than expected. Symptomatic MG achieved almost half of all positive NAAT. Two-thirds showed 23S rRNA macrolide resistance mutations (MRM)."

Clinical • Hepatitis C • Hepatology • Human Immunodeficiency Virus • Infectious Disease • Inflammation